본문 바로가기

기관정보

기관정보 기관정보상세

기관상세정보

학회일반현황
학회일반현황
학회명 국문 대한임상신경생리학회 기관구분 학회
영문 The Korean Society for clinical Neurophysiology 제재이력 변경이력
전화번호   팩스번호  
홈페이지 www.kscn.or.kr 이메일  
주소 [110741] 서울 종로구 인사동 대일빌딩 1111호
대표자 성명 김대성
소속 부산대학교 직위 교수
임기 2019-01-01 ~ 2020-12-31
실무자 성명 박희진 연락처(핸드폰)
기업단체구분
연구분야 일반신경학
행정인력수 1명 전임연구인력수 0명
설립구분 기타 설립일자 1996-12-14
설립목적
											본 학회는 대한임상신경생리학회라 칭하며, 본회는 임상신경생리학회의 발전을 도모하고 이와 관련된 학술 사업을 통해 회원의 친목과 인류 건강의 향상에 기여함을 목적으로 한다. 본 학회의 회원구성은 정회원, 준회원, 특별회원,명예회원으로 한다, 구체적인 사업 내용은 신경과학 및 임상신경생리학에 관련된 연구,학술집회의 개최,학회지 및 간행물의 발간,정부, 산업계 및 공공단체와의 협동 연구 및 사업,임상신경생리학 관련 응용 기술의 개발 및 보급,국내외 학술 정보 교환 및 공동연구,기타 본회의 목적 달성에 관한 필요한 사업 을 통해 본회 목적 달성을 위해 필요한 사항이다.


										
연구윤리제정일 2008-06-10 원문서비스url
연구윤리내용
										Ethical Policy
1. Purpose
The purpose of this regulation is to establish and promote adherence
to research ethics in articles submitted to the Journal
of Annals of Clinical Neurophysiology (ACN), the authors, and
research conducted by the members of the Korean Society of
Clinical Neurophysiology (KSCN) as well as the other members
of researchers.

2. Researchers’ ethics
1) Researchers must be honest about their research. Researchers’
ethics are demanded in every stage of the research
process, including idea formation, study funding,
publication of outcomes, and fair compensation for the
study participants. More specifically, researchers must not
engage in the following research misconduct:
① “Fabrication” of nonexistent data or study findings.
② “Falsification” of study content or findings by artificially manipulating
study materials, equipment, or process, or arbitrarily
modifying or deleting data.
③ “Plagiarism,” where others’ ideas, study contents, or results
are taken without due approval or citation (However,
when citing published academic data, the data must be
accurately attributed to its correct source unless the data
falls under common sense. Further, data obtained from
personal contact can only be cited after obtaining consent
from the information provider).
④ “Unfair authorship acknowledgement,” where individuals
who have made scientific or technical contributions to the
study contents or results are not attributed authorship
without reasonable grounds, or individuals who have not
made scientific or technical contributions are attributed
authorship as a token of appreciation or respect (The order
of authors for publication of study articles or other types of
publications must be determined impartially depending
on the extent of contributions to the study irrespective of
the relative position or status of the individual; individuals
with low contributions to the study or article preparation
should be appreciated in footnotes or in the preface rather
than including them as an author).
⑤ “Duplicate submission or publication,” is where a manuscript
published or submitted for publication elsewhere is
submitted to or published in ACN, or where a manuscript
published or submitted for publication to ACN is reprinted
in another journal (authors may wish to use a portion of
previously published study results in their current study,
This it must be approved by the Editor-in-Chief of both
journals, and the Editor-in-Chief for the second publication
must be fully aware of the contents of the first publication.
The readership must also be notified of the second publication
when citing contents from the first publication).
⑥ Intentional hindrance of investigations about suspicions of
one’s own or others’ fraudulent activities.
⑦ Other actions that severely deviate from the range of actions
commonly accepted by the scientific community.
2) Studies that involve human subjects must generally adhere
to the 1964 declaration of Helsinki by the World Medical
Association (WMA). Details are as follows.
① Clinical trials must be reviewed and approved by the institutional
review board (IRB) of the corresponding institution,
and this should be stated in the text when preparing
the written article.
② Studies that involve human genome or embryo must
adhere to the “Bioethics and Safety Act.” Further, the study
must be reviewed and approved by the IRB of the institution,
and this should be stated in the text when preparing
the written article.
③ Study subjects must be given adequate explanation about
the purpose and method of the study and potential mental
and physical harm they may encounter during the
course of the study, and this should be stated in the text
when preparing the written article. Furthermore, a consent
form must be obtained from patients or caregivers when
there is a possibility of revealing the patient’s identity, such
as a facial image, and this should be stated in the text
when preparing the written article.
④ Consent forms are not waived for most experimental studies
that involve interventions, and a written consent form
must be obtained. Consent forms must be written in compliance
to ethical principles and standards based on relevant
laws, regulations, and the declaration of Helsinki, and
the principal investigator must obtain a written approval
from the IRB for the consent form, information sheet for
study participants, and other documents prior to beginning
the study. For clinical trials, the consent form suggested
by Korean Good Clinical Practice (KGCP), which has
been enforced by the Pharmaceutical Affairs Act, must be
prepared. Other experimental studies involving human
subjects must obtain approval stipulated by the Bioethics
and Safety Act. According to this act, written consent
forms containing the following information must be obtained
from study subjects prior to beginning the study:
(1) Study purpose (2) Participation period, procedure, and
method (3) Anticipated risks and benefits for the subjects
(4) Matters pertaining to the protection of personal information
(5) Compensation for any loss from study participation
(6) Matters pertaining to the disclosure of personal
information (7) Matters pertaining to the withdrawal of
consent.
3) The editorial board may request submission of documents
confirming the approval of the IRB or waiver of review if
necessary.
4) Studies involving animal subjects generally adhere to
the Guiding Principles in the Care and Use of Animals by
American Physiology Society.
5) The authors should disclose all potential conflicts of interest
including any research funding, other financial support,
and material support for the work, if any exists, in the
unblinded full title page. If there is a disclosure, the editors,
reviewers, and reader can approach the manuscripts after
understanding the situation.
6) Researchers must adhere to the general principles of citing
academic works.

3. Editor’s ethics
1) The editor is responsible for the decision about whether
to accept a submitted article and must respect the independence
of the author.
2) The editor must have the submitted article to be reviewed
by a reviewer with expertise in the corresponding field
and ability to provide unbiased judgment. When choosing
the reviewer, the editor must avoid reviewers who have
any form of personal relationship to the author, whether
friendly or hostile, to ensure objective review. However,
when the reviews of the same article significantly vary between
reviewers, the editor may seek consultation from a
third expert in the field.
3) The editor must promptly notify the IRB and appropriately
respond should events such as concerns pertaining to
reviewers’ review of a manuscript arise.

4. Reviewers’ ethics
1) Reviewers must faithfully review the submitted manuscripts
and notify the review results to the editor within
the period specified by the review regulation.
2) Reviewers must impartially assess according to objective
standards irrespective of one’s own academic beliefs, and
personal relationship, whether good or bad, with the
author. Reviewers must not reject a manuscript without
sufficient grounds or because it conflicts with one’s own
perspective or interpretation, and also must not review a
manuscript without reading it thoroughly.
3) Reviewers must abide by the confidentiality agreement
pertaining to the contents of the reviewing article. Unless
asking for advice for the review, it is not desirable for reviewers
to show the manuscript to others or discuss with
others. Furthermore, reviewers must not cite the content
of the manuscript until the journal containing the manuscript
is published.

5. Institutional Review Board (IRB)
1) An institutional review board (IRB; hereafter “the Board”)
shall be formed within Annals of Clinical Neurophysiology
(ACN) to review matters pertaining to research ethics.
2) The vice-president of the society will be the Board’s chairman,
and the society’s board of directors will determine
the composition and term of office for the Board.
3) The Board will be operated according to a separate regulation
determined by the Board.

6. Roles of the Board
The Board’s roles with regard to research ethics are as follows.
1) The Board reviews matters pertaining to research ethics
with regard to the publication of the journal, relevant articles
(e.g., original articles, case studies, brief communications,
reviews), and society members’ research works.
2) Should a violation of research ethics be reported, the
Board performs a wide investigation of the matter through
interviews with the accuser, accused, witnesses, and reference
witnesses, and with evidence. Once the accused research
ethics violation is determined to be true, the Board
may suggest appropriate disciplinary actions to the president.
3) Violations of research ethics, such as “fabrication,” “falsification,”
“plagiarism,” “unfair authorship attribution,” and “duplicate
publication,” shall be examined by the editorial board,
reviewed by the Board, then submitted to the board of
directors.
4) Violations of research ethics pertaining to the members of
the society shall be examined and reviewed by the Board
and submitted to the board of directors.

7. Processing of research ethics violations
1) Should violations of research ethics be reported, the chairman
of the Board promptly summons the Board to investigate
and review the matter and report the results to the
board of directors.
2) Anyone, including members and non-members, may report
violations of research ethics. The Board and the society
must adhere to the confidentiality agreement for matters
pertaining to the reporter’s personal information,
including affiliation and identity, and are obliged to protect
the reporter from any disadvantages.
3) The Board’s investigations and reviews of research ethics
violations must be kept confidential and must not be
against the interests of the society.
4) The Board must give an opportunity for the individual
accused of violating research ethics to protect oneself and
make a counterargument in writing or in person.
5) Records containing the results of the investigation of
research ethics violation and the actions taken shall be
stored by the society.
6) Once violation of research ethics pertaining to a submitted
manuscript is ruled, the board of directors shall announce
the matter and reject publication of the article that has violated
research ethics. If a published article is ruled to have
violated research ethics, the board of directors shall delete
the article from the list of articles of the journal and notify
the members and relevant academic institutions of the
pertinent matter. Depending on the extent of violation,
the main authors (first author, corresponding author) of
the article may be prohibited from submitting additional
articles to the journal for a certain period or permanently.
7) Once violation of research ethics pertaining to a member’s
research activities or submitted manuscript is ruled,
the board of directors shall announce the pertinent matter
and take one of the following actions against the violator
depending on the extent of the violation: ① warning,
② membership suspension, or ③ revocation of membership.
Matters not specified in this regulation shall abide by the official
order of the Ministry of Education and Science technology
(Volume 236), the “Guideline for ensuring research ethics,”
“Guideline for publication of medical articles” by the Korean Association
of Medical Journal Editors (KAMJE, www.kamje.or.kr),
and custom.
Supplementary Provision
1) This regulation is effective as of June 10, 2008.
										
연구윤리파일 ethical_policy(최신본).pdf   다운로드 

LoadingLoading....